Kornitzer Capital Management Inc. KS Sells 78,168 Shares of DexCom, Inc. (NASDAQ:DXCM)

Kornitzer Capital Management Inc. KS lowered its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 67.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,317 shares of the medical device company's stock after selling 78,168 shares during the quarter. Kornitzer Capital Management Inc. KS's holdings in DexCom were worth $2,569,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom in the 2nd quarter valued at $25,000. Sachetta LLC increased its holdings in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after purchasing an additional 171 shares during the last quarter. Crewe Advisors LLC bought a new position in shares of DexCom in the first quarter valued at about $29,000. Riverview Trust Co lifted its stake in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after buying an additional 232 shares during the last quarter. Finally, DT Investment Partners LLC boosted its holdings in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after buying an additional 315 shares during the period. Institutional investors own 97.75% of the company's stock.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company's stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.30% of the company's stock.

Analyst Ratings Changes

DXCM has been the topic of several research analyst reports. Sanford C. Bernstein increased their price target on shares of DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a report on Friday, October 25th. BTIG Research dropped their price target on DexCom from $156.00 to $120.00 and set a "buy" rating for the company in a report on Friday, July 26th. JPMorgan Chase & Co. lifted their price target on shares of DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Wells Fargo & Company increased their price target on DexCom from $80.00 to $90.00 and gave the stock an "overweight" rating in a research report on Friday, October 25th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom has a consensus rating of "Moderate Buy" and an average price target of $104.59.

DexCom Trading Up 1.5 %

Shares of DexCom stock traded up $1.05 during midday trading on Friday, reaching $69.96. The company had a trading volume of 3,153,680 shares, compared to its average volume of 4,825,686. The stock has a fifty day moving average price of $69.66 and a 200 day moving average price of $93.70. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a market cap of $27.33 billion, a PE ratio of 41.89, a P/E/G ratio of 2.10 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.